These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
745 related articles for article (PubMed ID: 21631695)
1. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Debruyne F; Barkin J; van Erps P; Reis M; Tammela TL; Roehrborn C; Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension. Na Y; Ye Z; Zhang S; Clin Drug Investig; 2012 Jan; 32(1):29-39. PubMed ID: 22017520 [TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630 [TBL] [Abstract][Full Text] [Related]
5. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029 [TBL] [Abstract][Full Text] [Related]
6. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428 [TBL] [Abstract][Full Text] [Related]
7. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F; Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Roehrborn CG; Marks LS; Fenter T; Freedman S; Tuttle J; Gittleman M; Morrill B; Wolford ET Urology; 2004 Apr; 63(4):709-15. PubMed ID: 15072886 [TBL] [Abstract][Full Text] [Related]
9. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study. Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046 [TBL] [Abstract][Full Text] [Related]
10. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. Roehrborn CG; Lukkarinen O; Mark S; Siami P; Ramsdell J; Zinner N BJU Int; 2005 Sep; 96(4):572-7. PubMed ID: 16104912 [TBL] [Abstract][Full Text] [Related]
11. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement. Gittelman M; Ramsdell J; Young J; McNicholas T J Urol; 2006 Sep; 176(3):1045-50; discussion 1050. PubMed ID: 16890688 [TBL] [Abstract][Full Text] [Related]
12. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Naslund MJ; Miner M Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044 [TBL] [Abstract][Full Text] [Related]
13. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. Barkin J; Roehrborn CG; Siami P; Haillot O; Morrill B; Black L; Montorsi F; BJU Int; 2009 Apr; 103(7):919-26. PubMed ID: 19239460 [TBL] [Abstract][Full Text] [Related]
14. Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate. Ravish IR; Nerli RB; Amarkhed SS Arch Androl; 2007; 53(1):17-20. PubMed ID: 17364459 [TBL] [Abstract][Full Text] [Related]
15. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response. Marks LS; Roehrborn CG; Wolford E; Wilson TH J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742 [TBL] [Abstract][Full Text] [Related]
16. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia]. Botto H; Lan O; Poulain JE; Comenducci A Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658 [TBL] [Abstract][Full Text] [Related]
17. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816 [TBL] [Abstract][Full Text] [Related]
18. [The effects of dutasteride on voiding and storage symptoms in men with benign prostatic hyperplasia]. Tsukamoto T; Shirai T; Sakamoto S; Akiyama A; Takeuchi H; Yajima M; Terao T; Endo Y Hinyokika Kiyo; 2010 Dec; 56(12):677-82. PubMed ID: 21273805 [TBL] [Abstract][Full Text] [Related]
19. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group. Stoner E Arch Intern Med; 1994 Jan; 154(1):83-8. PubMed ID: 7505563 [TBL] [Abstract][Full Text] [Related]
20. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F; Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]